Japan
Metcela Inc. is a Japan-based startup dedicated to revolutionizing heart failure treatment with their slogan "Unleash the Cell Potential." Founded in 2016, the company has a clear mission - to develop and commercialize an effective and reasonably priced therapy for heart failure utilizing specific fibroblast cells known as "VCF," obtained from the patient’s own heart. Their approach to heart failure therapy sets them apart from others in the industry; rather than simply replacing what is damaged, they aim to enhance the cells’ own ability to heal.
Their last investment, a significant ¥1.87B Series C investment on 28 June 2022, attracted attention from renowned investors including Sony Innovation Fund, CEJ Fund, Cyberdyne, Reazon Holdings, and Japan Lifeline.
Metcela operates within the Biotechnology and Health Care industries, addressing a critical global health issue while also targeting commercial success. Their innovative approach and recent funding make them an intriguing prospect for venture capitalists seeking impactful investments in the biotech sector.
